(Q36066144)

12 August 2017

1 reference

title

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer (English)

1 reference

12 August 2017

Antonio Porcaro

0 references

Umberto Basso

0 references

Teodoro Sava

1 reference

12 August 2017

Gian Luigi Cetto

series ordinal

1 reference

12 August 2017

publication date

1 February 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

published in

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

53-62

1 reference

12 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Adrenal androgen blockade in relapsed prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Effect of High-dose Medroxyprogesterone Acetate on Plasma Hormone Levels and Pain Relief in Patients with Advanced Prostatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Oral etoposide in the treatment of hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Systemic treatment of hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

An EORTC phase II study of vindesine in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Prognostic indicators in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Estramustine Phosphate Sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.53

21 January 2018

Identifiers

DOI

10.1586/14737140.5.1.53

1 reference

release_ha5pjun7svgv7jsmftufmffj2y

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ha5pjun7svgv7jsmftufmffj2y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference